Monthly Factsheet - November 2025
Summary by AI BETAClose X
 |
Geiger Counter Limited Plc
Monthly Investor Report December 2025
(All Factsheet data is at 30 November 2025)
The full monthly factsheet is now available on the Company's website and a summary can be found below.
NCIM - Geiger Counter Ltd - Fund Page for Geiger Counter Ltd
Enquiries:
For the Investment Manager
Craig Cleland
Manulife CQS Investment Management
0207 201 5368
For the Company Secretary and Administrator
R&H Fund Services (Jersey) Limited
Natalie Weeks/Katie De La Cour
01534 825341/01534 825200
-----------------------------------------------------------------------
Fund Description
The objective of Geiger Counter Limited is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium industry. Up to 30% of the value of the Company's investment portfolio may be invested in other resource-related companies from outside the energy sector.
Portfolio Managers
Keith Watson and Robert Crayfourd
Key Advantages for the Investor
· Access to mining assets in the uranium sector
· May benefit from embedded subscription share
· Low correlation to major asset classes
Key Fund Facts1
|
Total Gross Assets |
£85.6m |
|
Reference Currency |
GBP |
|
Ordinary Shares: |
106,618,612 |
|
Net Asset Value |
66.17p |
|
Mid-Market Price |
55.00p |
|
Net gearing4 |
21.33% |
|
Discount |
(16.88%) |
Ordinary Share and NAV Performance2
|
|
One Month |
Three Months |
One Year |
Three Years |
Five Years |
|
|
(%) |
(%) |
(%) |
(%) |
(%) |
|
NAV |
(19.57) |
9.72 |
4.06 |
29.97 |
299.82 |
|
Share Price |
(10.57) |
10.89 |
1.85 |
15.06 |
214.29 |
Commentary3
The U3O8 prices declined nearly 8% in November, ending the month at $75.875/lb. An easing in concerns over access to critical minerals in Western economies, including the US and Europe, was a primary factor that weighed on spot prices. This followed a mid-month agreement by China to defer the ban on its exports of rare earth metals by one year to the end of 2026. The sentiment weighed heavily on the spot uranium price and related uranium mining equities, with the Fund NAV declining nearly 20% during November. This was similar to declines registered by the Solactive Uranium Pure Play Index and Sprott Uranium Pure Play ETF recorded in sterling terms.
There was little effect from the production guidance of the primary listed producers, Cameco and Kazatomprom. Following its production downgrade in late summer at McArthur River, due to technical difficulties encountered during the transition to new mining zones, Cameco reported weaker-than-expected Q3 profits. However, the group's overall uranium production of 4.4Mlb represented a marginally better-than-expected run rate for the quarter. Stronger output from Cigar Lake helped offset declines in output at McArthur. Elsewhere, state-owned Kazatomprom, the largest global producer of uranium, reported attributable uranium production of 8.8Mlb U3O8, as expected and flat on Q2. U3O8 sales volumes were higher than forecast, seemingly due to the timing of sales being recorded, and its full-year production guidance was unchanged.
Following Executive Order "Unleashing American Energy" issued by the Trump Administration in January, uranium was officially reinstated to the US list of critical minerals, having been removed in 2022, in recognition of the strategic importance of nuclear fuel to the nation's electricity supply. One benefit derived from its renewed designation is an ability to prioritize uranium development projects for federal permitting, as well as accelerating reviews by relevant regulatory authorities such as the EPA and Bureau of Land Management. Such developments help support the outlook for expansion of the Fund's US-based holdings. Reducing development timelines could significantly improve project values. Following publication of the Executive Order earlier in the year, the move had little impact on US-based uranium miners in November. The equities of most US-based companies fell in line with the wider sector. Ur-Energy lagged slightly more, with a slower ramp-up of its Shirley Basin ISR project weighing on group financials, which included the purchase of 100klbs of U3O8.
Elsewhere, Sweden's government ratified a significant policy shift, passing legislative changes to lift the country's uranium mining ban (in place since 2018) from 1 January 2026.
|
|
Gross Leverage2 (%) |
Commitment Leverage3 (%) |
|
Geiger Counter Ltd |
122 |
122 |
CQS (UK) LLP
4th Floor, One Strand, London WC2N 5HR, United Kingdom
T: +44 (0) 20 7201 6900 | F: +44 (0) 20 7201 1200
CQS (US), LLC
152 West 57th Street, 40th Floor, New York, NY 10019, US
T: +1 212 259 2900 | F: +1 212 259 2699
Tavistock Communications
18 St. Swithin's Lane, London EC4N 8AD
T: +44 20 7920 3150 | geigercounter@tavistock.co.uk
Sources: 1Summit Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. 2 Summit Fund Services Jersey Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document. 3Market data sourced from Bloomberg unless otherwise stated. The Company may since have exited some or all of the positions detailed in the commentary. 4 BMO, UxC, Company data September 2023. 5 www.eia.gov. 6CQS, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 7, 9 and 10 of Delegated Regulation 231/2013. 7CQS, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 8, 9, 10 and 11 of Delegated Regulation 3231/2013.
The Company has announced the fifth Subscription Rights Price of 37.20 pence on 1 May 2025. The exercise date for the fifth Subscription Right is expected to be 30 April 2026.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 6 hours ago Luceco
- 6 hours ago Helios Towers
- 7 hours ago Wise Class A
- 7 hours ago EDX Medical Group Plc
- 7 hours ago Naked Wines